Is Catalyst Pharmaceuticals Inc (CPRX) overvalued? · P/E 18, rev $491.7M
Catalyst Pharmaceuticals Inc (CPRX) is a biotechnology company listed on NASDAQ.
This page asks whether Catalyst Pharmaceuticals Inc (CPRX) looks expensive on cached numbers — not a short thesis.
Latest reported CPRX revenue for 2024-12-31 was $491.7M. Net income was $163.9M. Revenue was up 23.5% from 2023-12-31 to 2024-12-31. CPRX currently screens at market cap $3.84B and trailing P/E 18.2.
CPRX currently screens at market cap $3.84B and trailing P/E 18.2. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CPRX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CPRX stock page for the full model, not this heading.
Not investment advice.